Champions Oncology Inc
NASDAQ:CSBR
Champions Oncology Inc
NASDAQ:CSBR
Price:
4.9 USD
-4.48%
Market Closed
Updated:
May 7, 2024
Champions Oncology Inc
Net Income (Common)
|
Champions Oncology Inc
Net Income (Common) Peer Comparison
Comparables:
TMO
DHR
WST
A
IQV
Competitive Net Income (Common) Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Champions Oncology Inc
NASDAQ:CSBR
|
Net Income (Common)
-$9.7m
|
CAGR 3-Years
-113%
|
CAGR 5-Years
-108%
|
CAGR 10-Years
-3%
|
|
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
Net Income (Common)
$6B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
15%
|
CAGR 10-Years
17%
|
|
|
Danaher Corp
NYSE:DHR
|
Net Income (Common)
$8.1B
|
CAGR 3-Years
21%
|
CAGR 5-Years
27%
|
CAGR 10-Years
12%
|
|
|
West Pharmaceutical Services Inc
NYSE:WST
|
Net Income (Common)
$568.7m
|
CAGR 3-Years
10%
|
CAGR 5-Years
21%
|
CAGR 10-Years
18%
|
|
|
Agilent Technologies Inc
NYSE:A
|
Net Income (Common)
$1.2B
|
CAGR 3-Years
15%
|
CAGR 5-Years
2%
|
CAGR 10-Years
5%
|
|
|
IQVIA Holdings Inc
NYSE:IQV
|
Net Income (Common)
$1.4B
|
CAGR 3-Years
69%
|
CAGR 5-Years
39%
|
CAGR 10-Years
20%
|
See Also
What is Champions Oncology Inc's Net Income (Common)?
Net Income (Common)
-9.7m
USD
-9.7m
USD
Based on the financial report for Jan 31, 2024, Champions Oncology Inc's Net Income (Common) amounts to -9.7m USD.
What is Champions Oncology Inc's Net Income (Common) growth rate?
Net Income (Common) CAGR 10Y
-3%
-3%
Over the last year, the Net Income (Common) growth was -212%. The average annual Net Income (Common) growth rates for Champions Oncology Inc have been -113% over the past three years , -108% over the past five years , and -3% over the past ten years .
You don't have any saved screeners yet
